Research ReportJun 2, 2026
AI Research Insights
Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
Research ReportJun 2, 2026
First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: A Comparative Review of TOPAZ-1 (Durvalumab) and KEYNOTE-966 (Pembrolizumab)
Durvalumab/pembrolizumab plus GC are first-line standards for advanced BTC with comparable efficacy.
Research ReportJun 2, 2026
Active Surveillance versus Immediate Lobectomy for Low-Risk Papillary Thyroid Microcarcinoma (≤1 cm): A Narrative Scientific Review
AS matches lobectomy safety for low-risk PTMC with fewer complications and superior QoL.
Research ReportJun 1, 2026
BRAF V600E–Targeted Therapy Combined with PD-1 Blockade in Anaplastic Thyroid Carcinoma: Mechanistic Rationale, Emerging Clinical Evidence, and Resistance Biology
DTP triplet therapy boosts efficacy yet needs randomized trials for solid validation in BRAF-mutant ATC.
Research ReportJun 1, 2026
Targeted Therapy in Advanced Thyroid Cancer: Efficacy Benchmarks, Resistance Mechanisms, and Clinical Implications
Research ReportJun 1, 2026
Screening-Driven Inflation of Papillary Thyroid Carcinoma Incidence: A Comparative Analysis of China and the United States
PTC surge in China/US driven mostly by overdiagnosis, not true disease rise
Research ReportJun 1, 2026
Advanced/Metastatic Clear-Cell Renal Cell Carcinoma: A Comparative Treatment Review for China and the United States (2026)
IMDC stratifies ccRCC; China and US differ in approved regimens and sequencing.
Research ReportMay 28, 2026
Dosing and Safety Considerations for Bleomycin-, Etoposide-, and Platinum-Based Regimens in Testicular Cancer: A Narrative Review for Medical Professionals
BEP/EP regimens cure TGCTs; prioritize dose intensity, fertility, and long-term toxicity care.当前文件内容过长，豆包只阅读了前 3%。
Research ReportMay 28, 2026
Controversies in Testicular Cancer Management: Evidence Synthesis, Competing Hypotheses, and Decisive Study Designs
Controversies in early TGCT focus on surveillance vs chemo, plus salvage strategy choices.
Research ReportMay 28, 2026
First-line advanced clear-cell RCC: an evidence-based framework for choosing IO-TKI versus IO-IO
IO-TKI for rapid control, IO-IO for durable long-term survival in ccRCC.
Research ReportMay 26, 2026
Real‑world evidence for first‑line immuno‑oncology combinations in metastatic renal cell carcinoma: an evidence synthesis through May 2026
Research ReportMay 26, 2026
Dosing and Safety Considerations for Bleomycin-, Etoposide-, and Platinum-Based Regimens in Testicular Cancer: Practical Guidance for Current Practice
Chemotherapy regimens, dosing and monitoring for GCT focus on safety and long-term care.
Research ReportMay 26, 2026
Testicular Germ Cell Tumors 2021–2026: Biomarker Advances, De‑escalation, and the Implementation Gap in Europe and China
Novel biomarkers and tailored strategies advance TGCT care with global adoption barriers
Research ReportMay 25, 2026
BEP × 3 versus EP × 4 for IGCCCG Good‑Risk Testicular Germ Cell Tumors After Orchiectomy: An Evidence‑Based Narrative Review
Two regimens treat favorable GCT, balancing efficacy and distinct toxic risks
Research ReportMay 25, 2026
HIF‑2α Inhibitors in RCC and VHL‑Associated Tumors: A 2026 Global Competitive Review Benchmarked to Belzutifan
HIF‑2α inhibitors: Belzutifan leads; casdatifan/NKT2152 follow, with wide RCC/VHL whitespace.
Research ReportMay 25, 2026
Global Clinical-Stage Landscape in Urothelial Bladder Cancer (as of 2026-05-20)
UBC treatment evolves fast with ADC, ICI; FGFR and CAR-T remain vacant
Research ReportMay 22, 2026
Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-Based Chemotherapy as First-Line Therapy for Locally Advanced or Metastatic Urothelial Carcinoma: An Evidence-Based Narrative Review
EV plus pembrolizumab is the optimal first-line regimen for most advanced urothelial carcinoma patients, with platinum chemotherapy reserved for specific high-risk cases.
Research ReportMay 22, 2026
A Practical Biomarker Framework for Urothelial Bladder Cancer: Predictive Response, Resistance, Pharmacodynamic Engagement, and Safety Stratification in the Era of Precision Oncology
Biomarkers guide precise targeted therapy and safety management for urothelial bladder cancer.
Research ReportMay 22, 2026
A Practical Biomarker Framework for Urothelial Bladder Cancer: Predictive Response, Resistance, Pharmacodynamic Engagement, and Safety Stratification in the Era of Precision Oncology
Biomarkers guide precise targeted therapy and safety management for urothelial bladder cancer.
Research ReportMay 22, 2026
First-line systemic therapy for unresectable malignant pleural mesothelioma: platinum/pemetrexed chemotherapy versus nivolumab plus ipilimumab
Nivo+ipi beats chemo for unresectable MPM, especially non-epithelioid.